ADMS Adamas Pharmaceuticals, Inc.

17.28
+0.19  (1.11%)
Previous Close 17.09
Open 17.11
Price To book 2.61
Market Cap 379.85M
Shares 21,982,000
Volume 73,275
Short Ratio 19.33
Av. Daily Volume 144,008

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Dec 24 2014
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102
Multiple sclerosis (MS)
PDUFA date August 24, 2017.
ADS-5102
Levodopa-Induced Dyskinesia

Latest News

  1. 8:02 am Adamas Pharmaceuticals will present results from its Phase 2 proof-of-concept study of ADS-5102 extended-release capsules for the treatment of walking impairment in patients with multiple sclerosis at the ACTRIMS Forum 2017
  2. Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017
  3. Adamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : January 20, 2017
  4. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : January 19, 2017
  5. Adamas Pharmaceuticals Inc (ADMS) Is Up On PDUFA: What’s Next?
  6. Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
  7. Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
  8. Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
  9. Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
  10. Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
  11. Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy
  12. Mylan (MYL) Announces Multiple Generic Launches in the U.S.
  13. Mylan/Biocon's Herceptin Biosimilar Phase III Data Published
  14. Mylan (MYL) Launches Authorized Generic EpiPen at $300
  15. Is Craft Brew Alliance Inc (BREW) A Good Stock To Buy?
  16. Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
  17. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : December 5, 2016
  18. Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : November 23, 2016
  19. Moving Average Crossover Alert: Adamas Pharma (ADMS)
  20. ADAMAS PHARMACEUTICALS INC Financials